User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 36.00 35.00 37.00 36.00 36.00 36.00 3,449 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -21.9 -9.8 - 126

Advanced Oncotherapy Share Discussion Threads

Showing 5451 to 5474 of 5475 messages
Chat Pages: 219  218  217  216  215  214  213  212  211  210  209  208  Older
DateSubjectAuthorDiscuss
29/4/2021
17:38
There is a Goetz Partners research note 27/04/2021 on AVO (paid for by Co.) stating Outperformance and a target price of £1.35. It's a detailed piece of work (17 pages). The summary: Our Discounted Cash Flow (DCF) analysis for AVO is shown in CHART 14. We have chosen to value the company on a DCF basis for a number of reasons. Firstly, AVO is a relatively young company in terms of its commercialisation stage in PT and while the technology is older than sixty years, PT has only recently witnessed a significant uptake in clinical adoption. Secondly, AVO’s approach is new and commercially untested. However, the potential for AVO to build a strong position in the future radiation therapy market is significant and we note that the substantial potential upside derived from revenue sharing agreements are not included in our forecasts at this stage. For our DCF, we forecast AVO’s financial performance for 15 years to 2035E to capture the company’s long-term potential. Free cash flows (“FCF”) are discounted, and risk adjusted using a discount factor of 20%, which we feel is appropriate for a company such as AVO, capturing the commercial risk associated with the company achieving our forecasts. This yields a fair value of £1.35 per share, representing c.3.5x upside to current trading levels. Focus remains on commercial momentum growth and upcoming clinical inflection points While there is a growing case for adoption as evidence of treatments where LIGHT could be of benefit such as LEAP, we maintain the view that developing commercial traction remains the key driver for AVO over the next 12 - 18 months. We expect further news flow regarding system sales in line with upcoming clinical development inflection points including first patient treated, although AVO has not recently updated guidance on when this will occur. The LIGHT system is largely de risked from a technology perspective, in our view. However, despite the project being overseen by a number of world-renowned technical experts, and technology originally developed at CERN, we can appreciate why potential customers may not be willing to take a risk on the capital expenditure at this stage due to a lack of real-world evidence for the system. We therefore see the upcoming clinical development milestones as a key inflection point with the first human application of LIGHT likely to trigger an expansion of AVO’s order book.
robbiekeane
23/4/2021
12:21
Somebody needing to sell maybe. There isn't much trading so just one seller can have a big impact on the price. Would be nice to have an update, and some timelines.
gclark
23/4/2021
11:16
When this comes good it could be very sweet
hybrasil
22/4/2021
16:37
Have they just done a fundraise at 35? If so, must be the last one, mustn't it?
gclark
22/4/2021
16:32
Very quiet here... No news recently and share price drifting down.
uncleoswald
13/2/2021
18:32
robbiekeane thanks, just listened to the podcast with the AVO CEO which is just over 17 mins and very informative and would recommend, a good listen for both long term investors and those new trying to understand what AVO does and the potential.
pj84
13/2/2021
14:05
Nicolas Serandour interview with UK Investor hTTps://ukinvestormagazine.co.uk/advanced-oncotherapy-democratising-proton-beam-therapy-in-cancer-treatment/
robbiekeane
22/1/2021
10:58
Decent fundraise at not too much of a discount. Existing long term shareholders taking more. Probably what we need to kickstart meaningful production.
robbiekeane
06/1/2021
18:04
robbiekeane>> I agree but I am unaware that the first machine has been a)completed and b) approved by regulators. Maybe Monday update will enlighten.
twirl
06/1/2021
13:02
twirl, I think "pace of manufacture" is the only thing holding us back at this point.
robbiekeane
06/1/2021
12:48
Todays rns merely provides customers with finance as an alternative to the finance they will be able to obtain from other sources. Nevertheless we have seen how such schemes have enabled car manufacturers to con the public who mostly rent their new cars now. So maybe this will lead to more sales being marketted as a rental. I never had any doubt they could sell the machines and the 2 main problems seemed to be a) a machine that works and b) pace of manufacture. We may be enlightened on the first point on Monday. Hopefully not a repeat of previous similar teasing non specific BS updates. Not tempted.
twirl
06/1/2021
12:25
Reading between the lines of the RNS I suspect this good news also means that another slice of income or profit is leaving ACO to the funder. I still don't see this as a viable investment for anyone other than the incredibly highly paid board.
igbertsponk
06/1/2021
12:06
A very good announcement today. Probably why the share price has been slowly creeping up over the past couple of weeks. Now starting to motor.
robbiekeane
04/1/2021
09:28
Well I guess it is this year, or no year, for AVO. First patient due to be treated. Do we have expected date? Suppose with all that is happening, all dates will be fluid for first quarter of the year. But if first treatment is successful, then the share price should go into orbit. But If unsuccessful....then???? for some time at least.
gerhart
15/12/2020
15:11
Pring: Technical Analysis Explained- Head and Shoulders or Double Top do not send out any signal until the share price has fallen below the neckline thus confirming the pattern. You should not try and 'front-run' either pattern.
joevalue
26/11/2020
10:52
or it could meander about until the larger investors decided what price to put the next raft of dosh in at to keep the Board in clover.
igbertsponk
26/11/2020
10:47
The head and shoulders pattern is still developing. The share price could rise to a moderate peak, even a double top around 34p, before plunging to the low 20s or below. Or it could simply drop to around 20p from here.
daijavu
19/11/2020
10:59
The Directors have been handsomely rewarded for years and years of delay. Pity them not.
igbertsponk
18/11/2020
17:20
Looks like a head and shoulders to me. The drop comes next
daijavu
19/8/2020
14:15
justjill: I agree. It's just one of the indicators to look at I think. AVO is a good story but they have delayed and delayed and funding has been an issues so perhaps baner is right. However, I do think the directors have shown strength and not bottled it over the years, so I'd be surprised if they sold at the first chance to a bidder. They must have invested not just money but years of blood, sweat and tears too. To get a short term financial reward, when you consider what they could get eventually, would seem a bit er... short term (sic). As long as they can keep the funding oiled then I see this moving forward.
sea and sky
19/8/2020
08:08
One of the major players in this sector Will bid for AVO. Value - a multiple of the current level. When - as soon as first launch has proven successful. 2021?
baner
19/8/2020
07:47
Sea, we tend to forget, though "insider dealing" is illegal, directors always know much much more about what is happening and how things are progressing and so they can look further down the road. In my view this is huge, as I don't think Dr Sinclair spent over £45k on a red or black gamble.
justjill
18/8/2020
20:10
nice to see a director supporting ... hard to see why unless he knows something...
sea and sky
18/8/2020
18:22
Nice director (chairman )buy after the close £45000 worth at 32p ????
topman1966
Chat Pages: 219  218  217  216  215  214  213  212  211  210  209  208  Older
ADVFN Advertorial
Your Recent History
LSE
AVO
Advanced O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210507 14:33:03